Magali Taiel, Chief Medical Officer, will participate to the Mitochondria-Targeted Drug Development Summit to be held virtually from April 27 to 29, 2021.


Panel Discussion: Recognize the Financial Difficulty of Developing Drugs for Targeting Mitochondria & Moving Drugs to the Next Phase

Day 2:  Thursday April 29, 2021

Time:  9AM – 5PM EST | 3PM – 11PM CEST


Oral presentation:  Deep Dive into Gene Therapy & Editing when Targeting Mitochondria

Day 2:  Thursday April 29, 2021

Time:  2.4 PM EST | 8.45PM CEST

Title:  Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy (LHON)

  • Examine LHON and its main clinical aspects
  • Delve into late-stage development of Lumevoq Gene Therapy
  • Discuss regulatory pathways
  • Outline key learnings of Lumevoq gene therapy